imciromab pentetate

Trade name: myoscint

mAbapprovedImaging agent

Approved

Jul 3, 1996

Indium (111In) imciromab is a mouse monoclonal antibody labelled with the radioisotope Indium-111. It was used for cardiac imaging, but withdrawn in 1993. — Wikipedia

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1990s

  1. Jul 3, 1996

    Centocor — Earliest FDA Approval

  2. Jul 3, 1996

    Centocor — Marketing Organization

  3. Jul 3, 1996

    Centocor — NDA Organization

Indications

Mechanism of action

  • Myosin-2INHIBITOR

    MYH2 inhibitor

  • Unspecified targetOTHER

    Diagnostic (monoclonal antibody that is labelled with Indium (111In) for imaging)

Approval history

  • approvedJul 3, 1996

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Discontinued
Multi-specific
No
Imaging
111-Indium

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • (111)indium-labeled antimyosin antibody
  • c-4
  • c-4
  • imciromab
  • imciromab (111in)
  • imciromab in111
  • imciromab pentetate
  • imciromab pentetate
  • imciromab pentetate
  • imciromab pentetate
  • imciromab pentetate, radiolabeled product
  • indio-111-antiomiosina
  • indium-111-antimyosin
  • indium-111-antimyosin fab
  • indium (111in) imciromab
  • indium (111in) imciromab pentetate
  • indium antimyosin
  • indium in 111 imciromab pentetate
  • indium in 111 imciromab pentetate
  • indium in-111 imciromab pentetate
  • indium in-111 myoscint
  • myoscint
  • myoscint
  • myoscint
  • myoscint indium in-111
  • r1d10

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
CentocorFor profitMKTGJul 3, 1996
CentocorFor profitNDAJul 3, 1996